Clinical diagnostics and therapy of HIV-HBV-coinfected patients;HIV-HBV-koinfektion - Diagnostik und therapie

Deutsche Medizinische Wochenschrift

Volumn 131, Issue 34-35, 2006, Pages 1873-1877

  Koch, Stefanie ^a   Gobels K ^a   Oette, M ^a   Heintges, T ^a   Erhardt, A ^a   Haussinger D ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

HAART; Hepatitis B; HIV infection

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; AMDOXOVIR; AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; CLEVUDINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS A HEPATITIS B VACCINE; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VALTORCITABINE; ALPHA FETOPROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; BIOLOGICAL MARKER;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINOTRANSFERASE BLOOD LEVEL; BONE PAIN; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DEPRESSION; FEVER; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MORBIDITY; MORTALITY; RASH; REVIEW; SIDE EFFECT; VIRUS REPLICATION; VIRUS TRANSMISSION; BLOOD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; PROGNOSIS; TREATMENT OUTCOME; VIROLOGY;

ALPHA-FETOPROTEINS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; HEPATITIS B; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; PROGNOSIS; TREATMENT OUTCOME;

EID: 33749186773     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-949173     Document Type: Review

References (36)

1. Alberti A, Clumeck N, Collins S et al. Short statement of the first european consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615-624
2. Angus P, Vaughan R, Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-297
3. Bang L, Scott L. Emtricitabine. Drugs 2003; 63: 2413-2424
4. Baraclude TM. (entecavir) package insert. Princeton (NJ): Bristol Meyers Squibb Company; Stand: März 2005
5. Benhamou Y, Thibault V, Vig P et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006; 44: 62-67
6. Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol 2006; 44: 90-94
7. Brook M, Gilson R, Wilkins E. British HIV Association. BHIVA guidelines: coinfection with HIV and chronic hepatitis B virus. HIV Med 2003; 4: 42-51
8. Colin JF, Cazals-Hatem B, Loriot MA et al. Influence of HIV infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29: 1306-1310
9. Colonno RJ, Rose R, Levine SM et al. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II & III studies is only observed in lamivudine refractory patients. Hepatology 2004; 40: 661A
10. Craxi A, Antonucci C, Camma C. Treatment options in HBV. J Hepatol 2006; 44: 77-83
11. Dusheiko G. Candidates for therapy: HBV. J Hepatol 2006; 44: 84-89
12. Erhardt A, Blondin D, Hauck K et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 1009-1013
13. Häussinger D, Erhardt A, Oette M. Koinfektionen bei Hepatitis. Z Gastroenterol 2004; 42: 724-730
14. Hodge R. Telbivudine/torcitabine Idenix/Novartis. Curr Opin Investig Drugs 2004; 5: 232-241
15. Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998; 17: 6-13
16. Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic HBV infection in coinfected patients receiving lamivudine as a component of anti-HIV regimens. Clin Infect Dis 2001; 32: 963-969
17. Huang A. Entecavir in HIV-HBV Co-Infection: Week 48 results (ETV-038). Abstract H-415. Abstracts of the 45th Interscience conference on antimicrobial agents and chemotherapy. Washington, DC, 2005
18. Hung C, Hsiao C. Isolated antibody to hepatitis B core antigen in individuals infected with HIV-1. Clin Infect Dis 2003; 37: 1275-1276
19. Lacombe K, Massari V, Girard PM et al. Major role of hepatitis genotypes in liver fibrosis during coinfection with HIV. AIDS 2006; 20: 419-427
20. Marcellin P, Lau GK, Bonino F et al. Peginterferon alfa -2a alone, lamivudine alone, and the two in combination in patients with HbeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217
21. Marcellin P, Mommeja-Marin H, Sacks S et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004; 40: 140-148
22. Niederau C. Criteria for the treatment of chronic hepatitis b and d. Z Gastroenterologie 2004; 42: 682-686
23. Nunez M, Puoti M, Camino N, Soriano V. Treatment of chronic hepatitis B in the HIV-infected patients: present and future. Clin Infect Dis 2003; 37: 1678-1685
24. Perez-Olmeda M, Nunez M, Garcia-Samaniego J, Rios P, Gonzalez-Lahoz J, Soriano V. Distribution of hepatitis b virus genotypes in HIV-infected patients with chronic hepatitis B: therapeutic implications. AIDS Res Human Retroviruses 2003; 19: 657-659
25. Puoti M, Airoldi M, Bruno R et al. Hepatitis B virus co-infection in human immundeficiency virus-infected patient: epidemiology, natural history and treatment. Semin Liver Dis 2003; 23: 125-136
26. Rehermann B. Immune responses in hepatitis B virus infection. Semin Liver Dis 2003; 23: 21-37
27. Schildgen O, Schewe C, Vogel M et al. Successful therapy of hepatitis B with tenofovir in HIV infected patients failing previous adefovir and lamivudine treatment. AIDS 2004; 18: 2325-2327
28. Schildgen O, Sirma H, Funk A et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 355: 322-323
29. Scotto G, Palumbo E, Fazio V, Tartaglia A, Saracino A, Angarano G. Clinical and virological response to adefovir dipovixil for lamivudine-resistant HBeAg-negative hepatitis B. New Microbiol 2005; 28: 193-197
30. Sheldon JA, Corral A, Rodes B et al. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 2005; 19: 2036-2038
31. Soriano V, Puoti M, Bonacini M et al. Care of patients with chronic hepatitis B and HIV coinfection: recommendations from an HIV-HBV International Panel. Aids 2005; 19: 221-240
32. Tassopoulos NC, Volpes R, Pastore G et al., Lamivudine Precore Mutant Study Group. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. hepatology 1999; 29: 889-896
33. Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-3507
34. Thio CL, Seaberg EC, Jr. Skolasky R et al. Multicenter AIDS Cohort Study: HIV-1, hepatitis B virus and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926
35. Yoo BC, Kim JH, Lee KS et al. A 24-week clevudine monotherapy produced profound on-treatment viral suppression as well as sustained viral suppression and normalisation of aminotransferase levels for 24 weeks off-treatment in HBeAg(+) chronic hepatitis B patients. Hepatology 2005; 42: 270
36. Zoulim F. Assessment of treatment efficacy in HBV infection and disease. J Hepatol 2006; 44: 95-99